Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: Prospective cohort study

BMJ Open

Volumn 5, Issue 3, 2015, Pages

  Hippisley Cox, Julia ^a   Coupland, Carol ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST CANCER; CANCER CENTER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CLASSIFICATION ALGORITHM; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; ESOPHAGUS CANCER; ETHNICITY; FAMILY HISTORY; FEMALE; FOLLOW UP; GASTRO OESOPHAGEAL CANCER; GENERAL PRACTICE; GENERAL PRACTITIONER; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; INTESTINE CANCER; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUTH CANCER; OVARY CANCER; PANCREAS CANCER; PREDICTION; PROSPECTIVE STUDY; PROSTATE CANCER; SMOKING; STOMACH CANCER; UNITED KINGDOM; UTERUS CANCER; VALIDATION STUDY; VERY ELDERLY; AGE; ALGORITHM; BIPOLAR DISORDER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRINKING BEHAVIOR; ENGLAND; ETHNOLOGY; FORECASTING; GENETICS; HORMONE SUBSTITUTION; INCIDENCE; MIDDLE AGED; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; POVERTY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCHIZOPHRENIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ALGORITHMS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY MASS INDEX; COMORBIDITY; CONTRACEPTIVES, ORAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENGLAND; FEMALE; FORECASTING; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; POVERTY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SCHIZOPHRENIA; SMOKING;

EID: 84926468626     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-007825     Document Type: Article

References (98)

1. Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007;8:773-83.
2. Department of Health. The Cancer Reform Strategy. In: Health Do, ed. London: Department of Health, 2007.
3. Hippisley-Cox J, Coupland C. Identifying patients with suspected gastro-oesophageal cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2011;61:e707-14.
4. Hippisley-Cox J, Coupland C. Identifying patients with suspected lung cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2011;61:e715-23.
5. Hippisley-Cox J, Coupland C. Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. BMJ 2012;344.
6. Hippisley-Cox J, Coupland C. Identifying patients with suspected colorectal cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2012;62:e29-37.
7. Hippisley-Cox J, Coupland C. Identifying patients with suspected pancreatic cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2012;62:e38-45.
8. Hippisley-Cox J, Coupland C. Identifying patients with suspected renal tract cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2012;62:e251-60.
9. Hippisley-Cox J, Coupland C. Symptoms and risk factors to identify women with suspected cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2013;63:11-21.
10. Hippisley-Cox J, Coupland C. Symptoms and risk factors to identify men with suspected cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2013;63:1-10.
11. Office for National Statistics. Ten most common cancers among males and females. 2014. http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations-england-series-mb1-/no-43-2012/info-most-common-cancers.html
12. Hippisley-Cox J, Coupland C. Predicting risk of emergency admission to hospital using primary care data: derivation and validation of QAdmissions score. BMJ Open 2013;3:e003482.
13. Hippisley-Cox J. Validity and completeness of the NHS Number in primary and secondary care electronic data in England 1991 -2013. 2013;1. Hippisley-Cox J. Validity and completeness of the NHS number in primary and secondary care: electronic data in England 1991-2013. http://eprints.nottingham.ac.uk/3153/ (accessed Jun 2013).
14. Hippisley-Cox J, Vinogradova Y, Coupland C, et al. Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry 2007;64:1368-76.
15. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
16. Hippisley-Cox J, Coupland C. Individualising the risks of statins in men and women in England and Wales: population-based cohort study. Heart 2010;96:939-47.
17. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies. Br J Cancer 2011;105:452-9.
18. th Jul 2014).
19. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.
20. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
21. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 2008;94:34-9.
22. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ 2009;339:b2584.
23. Schafer J, Graham J. Missing data: our view of the state of the art. Psychol Methods 2002;7:147-77.
24. Group TAM. Academic Medicine: problems and solutions. BMJ 1989;298:573-9.
25. Steyerberg EW, van Veen M. Imputation is beneficial for handling missing data in predictive models. J Epidemiol Community Health 2007;60:979.
26. Moons KGM, Donders RART, Stijnen T, et al. Using the outcome for imputation of missing predictor values was preferred. J Epidemiol Community Health 2006;59:1092.
27. Rubin DB. Multiple imputation for non-response in surveys. New York: John Wiley, 1987.
28. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28:964-74.
29. Hosmer D, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, Inc., 1989.
30. Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. BMJ Open 2014;4: e005809.
31. Royston P. Explained variation for survival models. Stata J 2006;6:1-14.
32. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004;23:723-48.
33. Tsoi KK, Pau CY, Wu WK, et al. Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 2009;7:682-8.e1-5.
34. Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007;165:1424-33.
35. La Torre G, Chiaradia G, Gianfagna F, et al. Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years. Tumori 2009;95:13-22.
36. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking:40 years' observations on male British doctors. BMJ 1994;309:901-11.
37. Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer 2011;105(Suppl 2):S77-81.
38. Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2012;23:1880-8.
39. Zou L, Zhong R, Shen N, et al. Non-linear dose-response relationship between cigarette smoking and pancreatic cancer risk: evidence from a meta-analysis of 42 observational studies. Eur J Cancer 2014;50:193-203.
40. Viswanathan AN, Feskanich D, De Vivo I, et al. Smoking and the risk of endometrial cancer: results from the Nurses' Health Study. Int J Cancer 2005;114:996-1001.
41. Allen NE, Beral V, Casabonne D, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst 2009;101:296-305.
42. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002;87:1234-45.
43. Weikert C, Dietrich T, Boeing H, et al. Lifetime and baseline alcohol intake and risk of cancer of the upper aero-digestive tract in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Int J Cancer 2009;125:406-12.
44. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91:789-94.
45. Pharoah PD, Day NE, Duffy S, et al. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997;71:800-9.
46. Collaborative Group on Hormonal Factors in Breast C. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-99.
47. Fearnhead NS, Wilding JL, Bodmer WF. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 2002;64:27-43.
48. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006;42:216-27.
49. Cote ML, Liu M, Bonassi S, et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer 2012;48:1957-68.
50. Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev 2010;20:231-8.
51. Granstrom C, Sundquist J, Hemminki K. Population attributable fractions for ovarian cancer in Swedish women by morphological type. Br J Cancer 2008;98:199-205.
52. Cancer CGoHFiB. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
53. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
54. Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 2013;105:526-35.
55. Havrilesky LJ, Gierisch JM, Moorman PG, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep) 2013(212):1-514.
56. Salehi F, Dunfield L, Phillips KP, et al. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 2008;11:301-21.
57. Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19:789-99.
58. Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014;39:645-59.
59. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-83.
60. Duell EJ, Lucenteforte E, Olson SH, et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012;23:2964-70.
61. Zhou WB, Xue DQ, Liu XA, et al. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol 2011;137:1053-60.
62. Torrey EF. Prostate cancer and schizophrenia. Urology 2006;68:1280-3.
63. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-12.
64. Jiang Y, Ben Q, Shen H, et al. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2011;26:863-76.
65. Kramer HU, Schottker B, Raum E, et al. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. Eur J Cancer 2012;48:1269-82.
66. Luo W, Cao Y, Liao C, et al . Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of twenty four cohort studies. Colorectal Dis 2011; doi:10.1111/j.1463-1318.2011.02875.x.
67. Wu L, Yu C, Jiang H, et al. Diabetes mellitus and the occurrence of colorectal cancer: an updated meta-analysis of cohort studies. Diabetes Technol Ther 2013;15:419-27.
68. Shimoyama S. Diabetes mellitus carries a risk of gastric cancer: a meta-analysis. WJG 2013;19:6902-10.
69. Starup-Linde J, Karlstad O, Eriksen SA, et al. CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis. Curr Drug Saf 2013;8:296-332.
70. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011;47:1928-37.
71. Zhang ZH, Su PY, Hao JH, et al. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer 2013;23:294-303.
72. Zhang F, Yang Y, Skrip L, et al. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol 2012;49(Suppl 1):S235-46.
73. Xu H, Mao SH, Ding GX, et al. Diabetes mellitus reduces prostate cancer risk - no function of age at diagnosis or duration of disease. Asian Pac J Cancer Prev 2013;14:441-7.
74. UK CR. Cancer incidence and survival by major ethnic group in England, 2002-2006. Secondary Cancer incidence and survival by major ethnic group in England, 2002 -2006. 2009. http://publications. cancerresearchuk.org/cancerstats/statssurvival/incidence-survival-ethnicity.html.html
75. Ben-Shlomo Y, Evans S, Ibrahim F, et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur Urol 2008;53:99-105.
76. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 2011;11:83.
77. Jegu J, Colonna M, Daubisse-Marliac L, et al. The effect of patient characteristics on second primary cancer risk in France. BMC Cancer 2014;14:94.
78. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin 's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-94.
79. National Clinical Guideline Centre. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London 2014:286.
80. Hippisley-Cox J, Coupland C, Robson J, et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009;338:b880.
81. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 2012;344:e3427.
82. Hippisley-Cox J, Coupland C. Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores. BMC Fam Pract 2010;11:49.
83. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ 2011;343: d4656.
84. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009;339:b4229.
85. Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ 2011;342:d3651.
86. Collins GS, Altman DG. External validation of the QDScore for predicting the 10-year risk of developing type 2 diabetes. Diabet Med 2011;28:599-607.
87. Majeed A. Sources, uses, strengths and limitations of data collected in primary care in England. Health Stat Q 2004;21:5-14.
88. Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ 2012;344:e4181.
89. Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 2010;340:c2442.
90. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010;362:986-93.
91. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015;347:78-81.
92. Hippisley-Cox J, Coupland C. QRISK2 - 2014 Annual Update Information, 2014:5.
93. Hippisley-Cox J. QDiabetes 2013 Annual Update Information Secondary QDiabetes 2013 Annual Update Information 2013. http://qdiabetes.org/QDiabetes-2013-Annual-Update-Information.pdf
94. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013;346:f2573.
95. Hippisley-Cox J, Coupland C. Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores. BMJ 2014;349:g4606.
96. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013;5: CD000165.
97. Kaner EF, Beyer F, Dickinson HO, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev 2007(2):CD004148.
98. Parkes G, Greenhalgh T, Griffin M, et al. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336:598-600.